Is pharmacotherapy enough for urgent weight loss in severely obese patients?

References

• Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care. 1991;14:802–23.
   PubMed Web of Science ®Google Scholar
• Wahlroos S, Phillips ML, Lewis MC, et al. Rapid significant weight loss and regional lipid deposition: implications for insulin sensitivity. Obes Res Clin Pract. 2007;1:7–16. PubMed PMID: 24351427.
   Web of Science ®Google Scholar
• van Wissen J, Bakker N, Doodeman HJ, et al. Preoperative methods to reduce liver volume in bariatric surgery: a systematic review. Obes Surg. 2016;26:251–256. PubMed PMID: 26123526.
   PubMed Web of Science ®Google Scholar
• Hemmingsson E, Johansson K, Eriksson J, et al. Weight loss and dropout during a commercial weight-loss program including a very-low-calorie diet, a low-calorie diet, or restricted normal food: observational cohort study. Am J Clin Nutr. 2012;96:953–961. PubMed PMID: 22990030.
   PubMed Web of Science ®Google Scholar
• Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring). 2006;14:1283–1293. PubMed PMID: 16988070.
   PubMed Web of Science ®Google Scholar
• Haywood CJ, Prendergast LA, Purcell K, et al. Very low calorie diets for weight loss in obese older adults-a randomized trial. J Gerontol A Biol Sci Med Sci. 2017;73:59–65. PubMed PMID: 28329121.
   PubMed Web of Science ®Google Scholar
• Vink RG, Roumans NJ, Arkenbosch LA, et al. The effect of rate of weight loss on long-term weight regain in adults with overweight and obesity. Obesity (Silver Spring). 2016;24:321–327. PubMed PMID: 26813524.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–362. PubMed PMID: 25590212.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637–649. PubMed PMID: 30122305.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352. PubMed PMID: 21481449.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–120. PubMed PMID: 20559296.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE obesity and prediabetes NN8022–1839 study group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22. PubMed PMID: 26132939.
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. BLOSSOM clinical trial group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–3077. PubMed PMID: 21795446.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275–286. PubMed PMID: 29397376.
   PubMed Web of Science ®Google Scholar
• Li Z, Hong K, Yip I, et al. Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study. Curr Ther Res Clin Exp. 2003;64:447–460. PubMed PMID: 24944395.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2015;39:187. PubMed PMID: 25311036.
   PubMed Web of Science ®Google Scholar
• Capristo E, Panunzi S, De Gaetano A, et al. Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: a three-arm non-randomised, controlled, pilot study. Diabetes Metab. 2018;44:235–242. PMID:29398254.
   PubMed Web of Science ®Google Scholar
• King WC, Hinerman AS, Belle SH, et al. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320:1560–1569. PubMed PMID: 30326125
   PubMed Web of Science ®Google Scholar
• Hanipah ZN, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Rel Dis.2018;14:93–98.
   PubMed Web of Science ®Google Scholar
• Toth AT, Gomez G, Shukla AP, et al. Weight loss medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Children (Basel). 2018;5:116. PubMed PMID: 30158481.
   Web of Science ®Google Scholar
• Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder. A radomized clinical trial. JAMA Psychiatry. 2017;74:719–728. PubMed PMID:28601891.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. PubMed PMID: 27295427.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844. PubMed PMID: 27633186.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. PubMed PMID: 26378978.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. PubMed PMID: 28605608.
   PubMed Web of Science ®Google Scholar
• le Roux C, Aroda V, Hemmingsson J, et al. Comparison of efficacy and safety of liraglutide 3.0 mg in individuals with BMI above and below 35 kg/m2: a post-hoc analysis. Obes Facts. 2017;10:531–544. PubMed PMID: 29145215.
   PubMed Web of Science ®Google Scholar
• Bays H, Pi-Sunyer X, Hemmingsson JU, et al. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin. 2017;33:225–229. PubMed PMID: 27817208.
   PubMed Web of Science ®Google Scholar
• Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:370–381. PubMed PMID:29483060.
   PubMed Web of Science ®Google Scholar
• Fujioka K, O’Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring). 2016;24:2278–2288. PubMed PMID: 27804269.
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Kiortsis DN, Catalán V. Precision medicine: diagnosis and management of obesity. Lancet Diabetes Endocrinol. 2018;6:164–166. PubMed PMID: 28919063.
   PubMed Web of Science ®Google Scholar